BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Chronic kidney disease clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for chronic kidney disease: 193 (117 sponsors; 37 newly posted in the last 180 days, 12 stopped in the last 180 days; 15 new-entrant sponsors). Momentum score 18.1, rank 33 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 25, Phase 2 30, Phase 3 44, Phase 4 8, N/A 84.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 15 | P3 6, NA 4, P4 1, P2 3, P1 1 | 3 | 4 |
| Novartis Pharmaceuticals NVS | 6 | P3 5, P1 1 | 0 | 0 |
| Eli Lilly and Company LLY | 4 | P3 3, P2 1 | 1 | 1 |
| Bayer | 8 | NA 6, P3 2 | 1 | 2 |
| Boehringer Ingelheim | 4 | P3 2, NA 2 | 0 | 4 |
| Shandong Suncadia Medicine Co., Ltd. | 3 | P3 2, P1 1 | 1 | 0 |
| Amgen AMGN | 2 | P3 2 | 0 | 0 |
| Kind Pharmaceuticals LLC | 2 | P3 2 | 0 | 2 |
| Novo Nordisk A/S NVO | 6 | NA 2, P1 1, P4 1, P2 1, P3 1 | 5 | 0 |
| Eledon Pharmaceuticals ELDN | 3 | P2 2, P3 1 | 1 | 1 |
| Prokidney PROK | 3 | P3 1, NA 2 | 0 | 0 |
| Biohaven Therapeutics Ltd. BHVN | 2 | P3 1, P1 1 | 1 | 0 |
| CSL Behring | 2 | P3 1, P1 1 | 1 | 0 |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2 | P3 1, P2 1 | 0 | 1 |
| Alebund Pharmaceuticals | 1 | P3 1 | 0 | 0 |
| Alexion Pharmaceuticals, Inc. | 1 | P3 1 | 0 | 0 |
| AMAG Pharmaceuticals, Inc. | 1 | P3 1 | 0 | 0 |
| Amicus Therapeutics | 1 | P3 1 | 0 | 1 |
| Astellas Pharma Global Development, Inc. | 1 | P3 1 | 0 | 0 |
| Biocad | 1 | P3 1 | 0 | 0 |
| Dr. F. Köhler Chemie GmbH | 1 | P3 1 | 0 | 0 |
| Ebima Clifford Okundaye | 1 | P3 1 | 0 | 0 |
| Genexine, Inc. | 1 | P3 1 | 0 | 0 |
| Humacyte, Inc. HUMA | 1 | P3 1 | 0 | 0 |
| Iperboreal Pharma Srl | 1 | P3 1 | 0 | 1 |
Recently stopped trials
- NCT04523727 Keryx Biopharmaceuticals - suspended: Sponsor decision Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Ki
- NCT04968184 Novo Nordisk A/S - terminated: Interim futility analysis showed primary endpoint not achieved Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
- NCT05746559 Alexion Pharmaceuticals, Inc. - terminated: The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population. ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
- NCT07216885 Mozarc Medical US LLC - terminated: Due to funding the study has been stopped. All subjects enrolled have completed the follow-up and have exited the study. Solv Multi-Pass Hemodialysis System In-Center Clinical Study
- NCT06995144 Sarfez Pharmaceuticals, Inc. - withdrawn: No participants enrolled Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
- NCT07223502 Sarfez Pharmaceuticals, Inc. - withdrawn: No recruitment A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide
- NCT06598631 Eli Lilly and Company - withdrawn: Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the terminat Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
- NCT07020832 Apellis Pharmaceuticals, Inc. - withdrawn: The study was terminated following portfolio reprioritization and reallocation of resources to other development programs. The decision was Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Follow
- NCT02075463 GlaxoSmithKline - terminated: Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemod
- NCT05900050 Genfit - terminated: Sponsor Decision Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)
- NCT02859896 Sanofi - terminated: The study was conducted to fulfill a post-marketing commitment (PMC).FDA acknowledged the fulfillment of this PMC. Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperpara
- NCT04064827 AbbVie - terminated: Company Decision A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-26 est. | P3 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | NCT07122401 Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | Secondary Hyperparathyroidism, Chronic Kidney Disease | recruiting | 424 |
| 2026-12 est. | P1/P2 | Ingenia Therapeutics INC | NCT07231679 A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease | Healthy Volunteers; Chronic Kidney Disease | recruiting | 94 |
| 2026-12-10 est. | P2 | AstraZeneca AZN | NCT07222917 A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Ki | Chronic Kidney Disease and Hypertension | active not recruiting | 222 |
| 2026-12-31 est. | P3 | Boehringer Ingelheim | NCT06531824 EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Kidney Disease, Chronic | active not recruiting | 8371 |
| 2027-01 est. | P1/P2 | AION Healthspan, Inc. | NCT06721143 A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered | Chronic Kidney Disease Stage 3 | recruiting | 36 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P2/P3 | Ebima Clifford Okundaye | NCT06866236 Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression | Chronic Kidney Diseases; Acute Kidney Injury; Kidney Failure | not yet recruiting | 3000 |
| 2026-09-26 est. | P2 | AstraZeneca AZN | NCT06942910 A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and | Chronic Kidney Disease With High Proteinuria | active not recruiting | 224 |
| 2026-09-01 est. | P2 | Novo Nordisk A/S NVO | NCT06717698 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Chronic Kidney Disease | recruiting | 465 |
| 2026-09 est. | P2 | Maze Therapeutics MAZE | NCT06830629 A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease | Proteinuric Kidney Disease | recruiting | 74 |
| 2026-08-31 est. | P3 | AMAG Pharmaceuticals, Inc. | NCT03619850 A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Ped | Chronic Kidney Disease; Iron Deficiency Anemia | recruiting | 129 |
| 2026-08-14 | P2 | Boehringer Ingelheim | NCT06926660 A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease | Chronic Kidney Disease | completed | 492 |
| 2026-08-12 | P3 | Akebia Therapeutics AKBA | NCT06901505 To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis | Anemia of Chronic Kidney Disease | completed | 353 |
| 2026-08-11 est. | P2 | ZyVersa Therapeutics, Inc. | NCT06489340 P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease | Diabetic Kidney Disease | withdrawn | |
| 2026-07-20 | P2 | Vertex Pharmaceuticals Incorporated VERX | NCT06794996 Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities | Proteinuric Kidney Disease | completed | 42 |
| 2026-07-06 | P2 | Eli Lilly and Company LLY | NCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D | completed | 134 |
| 2026-07 est. | P3 | Akebia Therapeutics AKBA | NCT05082584 Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating | Anemia of Chronic Kidney Disease | withdrawn | |
| 2026-07 est. | P3 | Akebia Therapeutics AKBA | NCT05082571 Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease | Anemia of Chronic Kidney Disease | withdrawn | |
| 2026-06-20 est. | P3 | Alebund Pharmaceuticals | NCT06933472 A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China | Hyperphosphatemia; Chronic Kidney Disease, Receiving Dialysis; ESRD (End-Stage Renal Disease); Dialy | recruiting | 264 |
| 2026-06-09 | P3 | Novo Nordisk A/S NVO | NCT05021835 ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation | Cardiovascular Risk; Chronic Kidney Disease; Inflammation | completed | 6385 |
| 2026-05-27 | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07716618 A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD) | Chronic Kidney Disease | active not recruiting | 320 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "chronic kidney disease"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.